

## Special Issue

# Oncolytic Viruses as Immunotherapeutic Agents

### Message from the Guest Editor

In these challenging times, where pathogenic viruses such as SARS-CoV2 are at the center of attention, it is important to provide a platform for viruses that can help in treating cancer. These oncolytic viruses are non-pathogenic but instead they have the unique ability to specifically counteract malignant cells. One of the key features of oncolytic viruses is that they can create an immune-stimulatory inflammation in the tumor micro-environment. Therefore, oncolytic virotherapy can be classified as a novel type of targeted immunotherapy. An increasing amount of data suggests that oncolytic viruses can enhance efficacy of immunotherapy in resistant tumors. Still, many questions remain unanswered. In this Special Issue, we welcome original studies and reviews about oncolytic virus-host immune interactions, viro-immunotherapy mechanisms, and novel combinatorial approaches.

---

### Guest Editor

Dr. Nadine Van Montfoort

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

---

### Deadline for manuscript submissions

closed (1 May 2024)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.6  
Indexed in PubMed



[mdpi.com/si/125174](https://mdpi.com/si/125174)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.6  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).